Doximity (DOCS)
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$26.35-2.77%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · DOCS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -7.3% |
| Our one-year growth estimate | diamond | 6.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 13.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 21 industry peers · Company calendar date is not available
DOCS — earnings miss
Dated 2026-08-06
of this Current Report on Form 8-K, and the Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Revenue growth guidance will show if Doximity can keep expanding. This is key for investors.
Supportive ifManagement raises revenue growth forecast to more than 10%.
Worry ifManagement lowers revenue growth forecast to less than 8%.
Why it matters: The new CFO's plans can change Doximity's financial health. Success can help performance.
Watch forPositive financial results in the next quarter after the CFO change.
Also watch forNegative financial results in the next quarter after the CFO change.
Why it matters: A drop in net income margin shows less profit. This raises worries about cost control.
Worry ifNet income margin reported above 15%.
Less concerning ifNet income margin reported below 15%.
Why it matters: Keeping this growth rate is important for investor trust. It shows Doximity can grow in a tough market.
Worry ifRevenue grew more than 10% compared to last year.
Less concerning ifRevenue grew less than 10% compared to last year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$202 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $545 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,603 loss on $10,000 · 76.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This guidance shows if Doximity can make money. They face problems with revenue growth.
Supportive ifAdjusted EBITDA guidance meets or exceeds $81.5 million for Q2.
Worry ifAdjusted EBITDA guidance falls below $80.5 million for Q2.
Why it matters: Matthew Sonefeldt's leadership may change financial plans and results. His role is key for trust.
Watch forFinancial performance gets better with the new CFO. Metrics like net income and revenue grow.
Also watch forFinancial performance worsens or remains stagnant despite the new CFO.
Why it matters: The new CFO's approach can affect financial guidance and investor confidence. This is crucial for future growth.
Watch forThe new CFO provides a positive outlook and maintains or raises guidance.
Also watch forThe new CFO issues cautious guidance or lowers expectations.
Why it matters: This guidance is key to understanding if Doximity can sustain its revenue growth. Meeting or exceeding this range shows strong demand.
Supportive ifRevenue guidance for Q2 meets or exceeds $171 million.
Worry ifRevenue guidance for Q2 falls below $170 million.
Why it matters: A drop in the adjusted EBITDA margin shows less profit. It may mean cost issues.
Worry ifAdjusted EBITDA margin falls below 47.7% in Q2.
Less concerning ifAdjusted EBITDA margin stays the same or goes up above 47.7%.
Why it matters: More share buybacks show trust in the company's value. It shows a commitment to shareholders.
Supportive ifShare repurchases exceed $100 million in Q2.
Worry ifShare repurchases remain below $90 million in Q2.
Why it matters: This number shows how many users are engaged. Slower growth may mean market limits or more competition.
Worry ifActive prescriber growth is less than 30% year-over-year.
Less concerning ifActive prescriber growth is more than 30% year-over-year.